FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA
Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design
16 Jan 2026Industry news
FairJourney Bio (FJBio) has expanded its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the company’s advanced laboratories in San Diego, CA.
This strategic addition strengthens FJBio’s position as a trusted partner for pharmaceutical and biotechnology companies worldwide by providing accessible, high-resolution structural insights that accelerate antibody discovery, selection, and design.
By combining cutting-edge technology with FJBio’s team of expert scientists, the service offering ensures partners gain access to top-quality data and receive comprehensive guidance throughout the discovery and development process.
Benefitting from industry-leading, high-throughput cryo-EM capabilities, utilizing two state-of-the-art ThermoFisher Titan Krios 5 systems, the cryo-EM services enable rapid and scalable analysis, with models delivered within 2–3 weeks from sample delivery.
The offering supports both intermediate- and high-resolution validation of proteins, protein-protein, and protein-ligand complexes, producing high-quality and highly interpretable protein structures to inform confident decision-making.
Tailored specifically for antibody discovery, the cryo-EM services deliver value across the R&D value chain, supporting programs from early evaluation through to advanced optimization:
- Evaluation – Early structural insights into epitope diversity of immune libraries
- Discovery – cryo-EM-based hit discovery supported by sequence-from-structure workflows
- Selection – Structure-informed insights into therapeutic binding modes to guide lead selection
- Control – Computational protein design campaigns and development of next-generation synthetic libraries
“With the addition of cryo-EM services, supported by our high-end San Diego labs, we can provide our partners with the structural precision and expert support needed to accelerate the development of next-generation therapies,” said Dr. Christopher Arthur, CSO Structural Biology, FairJourney Bio.